Governance Cytokinetics, Incorporated

CYTK

US23282W6057

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 19:59:25 12/05/2026 BST			5-day change	1st Jan Change
74.46 ^USD	-0.13%		+12.88%	+17.34%

05-11	Cytokinetics Announces New Data Related to MYQORZO At ESC Heart Failure 2026	CI
05-07	Cytokinetics Prices Upsized $700 Million Share Offering	MT

Executive Committee: Cytokinetics, Incorporated

Manager

Positions heldSince

Robert Blum

62 year

Chief Executive Officer	31/12/2006
President	31/01/2006

Scott Jordan

Sales & Marketing

30/04/2021

Eric Brown

Chief Tech/Sci/R&D Officer

28/02/2018

Sung Lee

56 year

Comptroller/Controller/Auditor	30/12/2024
Director of Finance/CFO	07/05/2024

Stephen Heitner

Chief Tech/Sci/R&D Officer

28/02/2022

Christine Murray

65 year

General Counsel

31/03/2023

Steven Cook

Chief Tech/Sci/R&D Officer

30/06/2021

John Faurescu

General Counsel	28/02/2023
Corporate Secretary	28/02/2023

YulyMae DiNapoli

Human Resources Officer

31/10/2021

Kari Loeser

Compliance Officer

31/10/2021

Jeff Lotz

Chief Operating Officer	31/08/2021
Sales & Marketing	31/08/2021

Stuart Kupfer

Chief Tech/Sci/R&D Officer

31/12/2019

Diane Weiser

Investor Relations Contact	31/03/2015
Public Communications Contact	31/03/2015

Fady Malik

62 year

Chief Tech/Sci/R&D Officer

12/11/2015

Jeffrey Hessekiel

57 year

Chief Administrative Officer	13/11/2025
General Counsel	13/11/2025

Composition of the Board of Directors: Cytokinetics, Incorporated

Director

CommitteesSince

John Henderson

81 year

Audit Committee	07/04/2022
Governance Committee Chair	07/04/2022
Nominating Committee Chair	07/04/2022

Wendell Wierenga

78 year

Compensation Committee	30/09/2015
Governance Committee
Nominating Committee
Governance Committee Chair	30/09/2015
Nominating Committee Chair	30/09/2015
Compensation Committee Chair	19/09/2016

B. Parshall

71 year

Finance Committee
Audit Committee Chair	15/08/2022
Governance Committee
Nominating Committee

Muna Bhanji

63 year

Governance Committee	27/04/2022
Nominating Committee	27/04/2022
Compensation Committee	10/03/2021
Audit Committee	27/04/2022

James Daly

64 year

Audit Committee	26/06/2019
Compensation Committee	09/06/2016
Governance Committee	26/06/2019
Nominating Committee	26/06/2019

Edward Kaye

77 year

Audit Committee	19/05/2016
Compensation Committee	19/05/2016

Robert Harrington

65 year

Governance Committee	07/04/2022
Nominating Committee	07/04/2022

Nancy Wysenski

68 year

Compensation Committee Chair

19/11/2020

Robert Landry

62 year

Audit Committee

10/08/2025

Robert Blum

62 year

Director/Board Member

31/12/2006

Latest Appointments: Cytokinetics, Incorporated

11-14	Cytokinetics, Incorporated Appoints Jeffrey J. Hessekiel as Executive Vice President, Chief Legal and Administrative Officer, Effective as of November 14, 2025	CI
20/08/25	Cytokinetics Appoints Jim Daly to Board of Directors and as A Member of Compliance Committee Effective August 19, 2025	CI
31/03/25	Imbria Pharmaceuticals, Inc. announces tranche update	CI
11/02/25	Cytokinetics, Incorporated Announces the Appointment of Robert E. Landry to Its Board of Directors	CI
16/12/24	Cytokinetics, Incorporated Announces Executive Changes	CI
07/11/24	Cytokinetics, Incorporated Announces Resignation of Santo J. Costa as Board of Director	CI
15/08/24	Cytokinetics, Incorporated Announces the Appointment of Brett Pletcher as Executive Vice President and Chief Legal Officer	CI

More news

Former Officers and Directors: Cytokinetics, Incorporated

Insider

Positions held

SinceUntil

Brett Pletcher

General Counsel

18/08/2024

28/02/2025

Robert Wong

Comptroller/Controller/Auditor

14/05/2019

30/12/2024

Santo Costa

Director/Board Member	30/09/2010	31/10/2024
Independent Dir/Board Member	30/10/2011	31/10/2024

Sandy Smith

Director/Board Member	04/03/2012	14/05/2024
Independent Dir/Board Member	04/03/2012	14/05/2024

Daniel Casper

Chief Tech/Sci/R&D Officer

31/12/2016

31/03/2024

Ching Jaw

Director of Finance/CFO

25/06/2017

22/02/2024

Andrew Wolff

Chief Tech/Sci/R&D Officer

31/08/2004

30/06/2023

Bonnie Charpentier

Compliance Officer	31/12/2013	31/05/2023
General Counsel	31/12/2013	31/05/2023

David Cragg

Chief Administrative Officer	28/02/2019	30/06/2022
Human Resources Officer	31/01/2005	30/06/2022

Mark A. Schlossberg

General Counsel	30/04/2011	12/05/2022
Corporate Secretary	30/04/2011	12/05/2022

Leonard Patrick Gage

Director/Board Member	08/11/2009	16/03/2010
Chairman	16/03/2010	07/04/2022
Independent Dir/Board Member	04/11/2009	07/04/2022

Robert M. Califf

Director/Board Member	11/02/2018	15/02/2022
Independent Dir/Board Member	-	15/02/2022

Bettina Cockroft

Corporate Officer/Principal

31/07/2017

31/08/2019

Peter S. Roddy

Comptroller/Controller/Auditor

02/04/2017

14/05/2019

Whittemore Tingley

Chief Tech/Sci/R&D Officer

31/08/2017

30/11/2018

Joel Rothman

Corporate Officer/Principal

31/12/2016

31/08/2018

Caryn McDowell

Compliance Officer	17/05/2016	30/04/2018
General Counsel	30/04/2015	30/04/2018

Phillip Eric Lee

Director/Board Member

30/11/2015

28/02/2018

Sharon Barbari

Director of Finance/CFO	31/08/2004	25/06/2017
Corporate Secretary	07/05/2009	25/06/2017

Denise M. Gilbert

Director/Board Member	13/05/2008	19/05/2015
Independent Dir/Board Member	13/05/2008	19/05/2015

Conrad Jordaan

Corporate Officer/Principal

31/12/2013

Stephen M. Dow

Director/Board Member	31/03/1998	21/05/2013
Independent Dir/Board Member	30/10/2011	21/05/2013

James A. Spudich

Director/Board Member	31/12/1996	04/03/2012
Founder	31/12/1996	04/03/2012

David J. Morgans

Chief Tech/Sci/R&D Officer

30/09/2000

30/10/2011

A. Grant Heidrich

Director/Board Member

31/03/1998

08/02/2011

Michael Schmertzler

Director/Board Member

31/03/2003

31/10/2010

James H. Sabry

Chairman	14/03/2010	14/03/2010
Founder	31/12/1996	14/03/2010

Michael S. Rabson

General Counsel

29/02/2008

14/02/2010

Alan Russell

Corporate Officer/Principal

31/01/2002

31/01/2010

Mark McDade

Director/Board Member

30/06/2009

Jay K. Trautman

Chief Tech/Sci/R&D Officer

31/05/2002

29/09/2008

Charles Homcy

Director/Board Member

31/12/2007

Jeffrey Finer

Private Equity Investor

31/12/1997

01/01/2007

Larry Mattheakis

Chief Tech/Sci/R&D Officer

31/12/2001

31/12/2006

John Mao

Corporate Officer/Principal

30/10/2011

Marjorie C. Wagman

General Counsel

31/07/2005

William J. Rutter

Director/Board Member

04/04/2005

Karen S. Wright

Director of Finance/CFO

31/10/2001

30/11/2004

Lawrence S B Goldstein

Founder

31/12/1996

Ronald D Vale

Founder

31/12/1996

Joe Burris

Corporate Officer/Principal

Erik Atkisson

Compliance Officer	-	-
General Counsel	-	-

T. S. Harigopal

Chief Tech/Sci/R&D Officer

Joanna L. Goldstein

Public Communications Contact	-	-
Sales & Marketing	-	31/03/2014

Han-Jie Zhou

Corporate Officer/Principal

Jesse M. Cedarbaum

Corporate Officer/Principal

30/10/2011

Eugeni Vaisberg

Corporate Officer/Principal

Serge Lichtsteiner

Corporate Officer/Principal

Anne Moon Crompton

Corporate Officer/Principal

Gail A. Sheridan

Human Resources Officer

Gary Sams

Corporate Officer/Principal

Christopher S. Keenan

Investor Relations Contact	19/10/2011	30/10/2011
Public Communications Contact	-	-

Adam Tomasi

Corporate Officer/Principal

Zarak Khurshid

Corporate Officer/Principal

James Ahlers

Corporate Officer/Principal

Stefan Ryser

Director/Board Member

Nolan Sigal

Chief Tech/Sci/R&D Officer

Sunil Karnawat

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	22
Female	7

Of which Executive Committee

Male	11
Female	4

Of which Directors

Male	7
Female	3

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

Employees

673

Sector

Biotechnology & Medical Research

More about the company